A Simple and Fast Assay Based on Carboxyfluorescein-Loaded Liposome for Quantitative DNA Detection by Sforzi, Jacopo et al.
A Simple and Fast Assay Based on Carboxyfluorescein-Loaded
Liposome for Quantitative DNA Detection
Jacopo Sforzi,† Giuseppe Ferrauto,*,† Silvio Aime,†,‡ and Simonetta Geninatti Crich†
†Molecular Imaging Center, Department of Molecular Biotechnology and Health Sciences and ‡IBB-CNR, c/o Molecular
Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy
*S Supporting Information
ABSTRACT: The development of an innovative and easy way to
run assays for the quantitative detection of DNA present in
biological fluids (i.e., blood, urine, and saliva) is of great interest for
early diagnosis (e.g., tumors) and personalized medicine. Herein, a
new quantitative assay based on the use of highly sensitive
carboxyfluorescein-loaded liposomes as signal amplification systems
is reported. The method has been tested for the detection of low
amounts of DNA sequences. The reported proof of concept
exploits a target DNA molecule as a linker between two
complementary oligonucleotides. One oligonucleotide is biotinylated at its 3′ end and binds to streptavidin-coupled magnetic
beads, whereas the other one is conjugated to a cholesterol molecule incorporated in the phospholipidic bilayer of the
fluorescent liposomes. In the presence of the target fragment, the correct formation of a construct takes place as witnessed by a
strong fluorescence signal, amplified by dissolving lipidic nanoparticles with Triton X-100. The system is able to detect specific
nucleotide sequences with a very low detection threshold of target DNA (tens of picomolar). The assay allows the detection of
both single- and double-stranded DNA. Studies performed in human blood serum show the correct assembling of the probe but
with a reduction of limit of detection (up to ∼1 nM). This liposome signal amplification strategy could be used not only for the
detection of DNA but also for other nucleic acids (mRNA; microRNA) that are difficult to be quantified by currently available
protocols.
■ INTRODUCTION
The access to new, fast, and low-cost molecular diagnostic
platforms is crucial to enable more effective monitoring and
personalized treatments in cancer patients. In fact, the rapid
and accurate detection of genomic alterations is at the basis of
both the early diagnosis and the selection of the correct
targeted therapy.1 Moreover, in addition to neoplastic diseases,
nucleic acids may represent potential markers for a wide array
of pathologies, including metabolic, inflammatory, and
infectious diseases.2 Despite the fact that standard protocols
are still based on tissue biopsies to identify possible genomic
alterations, these methodologies are limited by the difficulties
related to the low accessibility of tumor tissue and by the risks
associated with the repetition of many tissue sampling.3
Recently, the sampling of biological liquids (i.e., blood, serum,
urine, and saliva) has been recognized as an alternative source
of nucleic acids for diagnosis of diseases.1,4,5 In a liquid biopsy
technique, great attention is devoted to the detection of the so-
called circulating tumor DNAs (ctDNAs), a class of tumor-
derived DNAs that are not associated with cells and are
fragmented in the bloodstream.6
In general, only very low amounts of ctDNA are present in
healthy patients. Conversely, significant levels of ctDNA can be
found in cancer.5,7,8 The methods routinely used for DNA/
RNA detection involve two steps, namely, (i) the in vitro
amplification of the sequence of interest (by polymerase chain
reaction, PCR, or reverse transcription PCR, RT-PCR) and
(ii) the detection of target DNA/RNA by electrophoresis,
southern/northern blots, sandwich hybridization assays, or
next-generation sequencing.8,9 The most innovative and best
performing methodologies are represented by digital droplet
PCR (ddPCR) and beads, emulsification, amplification, and
magnetics (BEAMing). Both of them show several advantages
and disadvantages.10,11 The ddPCR methodology utilizes a
droplet generator that allows the partition of single pieces of
DNA into droplets using an oil/water emulsion. The routine
detection of ctDNA is still hampered in the clinical practice not
only for an intrinsic lack of sensitivity/specificity for ctDNA
but also because the currently available procedures require a
high level of expertise and a long execution time.12 Moreover,
the facilities necessary for the analysis, as flow cytometry and
sequencing machineries, are present in specialized and certified
laboratories for this kind of testing but are not always available
in ordinary diagnostic laboratories.13
Alternatively, there are many examples of sandwich hybrid-
ization protocols based on the use of highly sensitive
radioactive probes14 or gold or fluorescent nanoparticles.15−17
The latter ones are preferred to the radioactive probes for
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obvious safety reasons, although they are less sensitive.18
Hence, the development of highly sensitive fluorescence-based
methods for ctDNA detection may be attractive but
challenging. In fact, this could help overcome the drawbacks
of classical molecular biology assays (i.e., the need of a facility
and expert staff)19 without the need to use hazardous
radioactive probes.
Useful routes to pursue the signal amplification may be
provided by the use of nanoparticles.20 For example,
fluorescein-encapsulating liposomes were reported to provide
a 1000-fold decrease of limit of detection (LOD), with respect
to fluorophore-labeled antibodies, in a sandwich hybridization-
based flow injection analysis system.21 Baeumner et al.
proposed an assay based on dye-loaded liposomes, bearing
oligonucleotides (complementary to the target DNA) on their
outer surface and polyethersulfone membranes with streptavi-
din immobilized in the detection area.22 The target DNA of
interest acts as a linker between the two shorter oligonucleo-
tide capture probes. Upon loading high amounts of sulforhod-
amine B (SR-B) inside liposomal nanoparticles, the detection
threshold was as low as 1 nM analyte.
Starting from these results, herein, we propose a
reproducible, versatile, and fast assay for DNA detection and
quantification based on the use of highly stable liposomes
loaded with fluorescent dyes that can be stored at 4 °C for 4
months without degradation. The proposed method does not
require neither a high expertise level nor the use of radioactive
molecules. It is based on the use of carboxyfluorescein (CF)-
loaded liposomes functionalized in the lipidic bilayer with a
cholesterol-tagged DNA sequence, which is complementary to
a portion of the target DNA.
The proof of concept of the proposed assay deals with the
capture of both single- and double-stranded DNA (ssDNA and
dsDNA, respectively) molecules using complementary oligo-
nucleotides, exploiting the target ssDNA or dsDNA as a linker
between two artificial strands. These strands are bound to dye-
encapsulating liposomes through a cholesterol molecule and to
streptavidin-coated magnetic beads via a biotin molecule. To
observe the fluorescent signal from the high concentrated
liposome payload, the lipidic nanoparticles were disrupted with
Triton X-100 obtaining a high increase of signal intensity.
■ RESULTS AND DISCUSSION
Assay Description. The assay consists of the following
four steps:
1) Commercially available magnetic beads functionalized
with streptavidin molecules (Strep Mag) are incubated
with a selected 18 base pair (bp) long ssDNA. This
ssDNA, referred to as ANCHOR hereafter, was
previously functionalized with a biotin-TEG group at
its 5′ end to bind streptavidin. The ANCHOR fragment
was specifically designed to be complementary with the
first 18 nucleotides present on the 3′ region of the
fragment to be detected (referred to as TARGET
hereinafter) (Figure 1).
2) Magnetic beads, covered with ANCHOR fragments, are
incubated for 30 min with the TARGET containing
solution. In the herein reported proof of concept, this
fragment was designed to be 36 bp long. After three
washing steps with Hepes/NaCl buffer, the unbound
TARGET molecules and every other component
possibly present in the matrix were washed out.
3) The 5′ portion of the TARGET fragments bound to the
ANCHOR can recognize a third fragment hereinafter
called PROBE. This third fragment, functionalized with
a cholesterol moiety at its 3′ end, was previously
intercalated in the phospholipidic bilayers of a liposome
loaded with a highly concentrated solution of a
fluorescent dye. The high concentration of the dye
inside the liposome aqueous cavity causes an extensive
“quenching” of the detectable fluorescence.23
4) After washing, to amplify the fluorescence signal,
liposomes are destroyed with Triton X-100. The signal
detected is directly proportional to the amount of the
TARGET fragment bound to magnetic beads through
ANCHOR.
Liposome Characterization. The used liposomes are
prepared with 100% DPPC, a saturated phospholipid that
ensures good membrane stability, avoiding leakage of the
fluorescent molecule from the liposome core. The average
diameter measured by dynamic light scattering (DLS) was of
110 ± 31 nm with a PDI value of 0.106 ± 0.007. Among the
commercially available dyes, CF was chosen due to its high
solubility in water, its high quantum yield (Φ = 0.92),24 its low
Figure 1. Assay proof of concept: step 1: Streptavidin Mag Sepharose beads interact with the biotinylated ANCHOR fragment. Step 2: 18
nucleotides of the ANCHOR fragment recognize specific complementary sequence on the TARGET fragment. Step 3: cholesteryl-tagged PROBE
fragment, conjugated with 50 mM CF liposome, interacts with the free 18 bp long portion of the TARGET fragment.
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commercial cost, and the compatibility with a wide array of
detectors commonly present in analytical laboratories. The
maximum loading CF concentration was set at 50 mM. Higher
CF concentrations were tested (e.g., 75 and 100 mM), but the
resulting liposomal formulations, which display a PDI value
higher than 0.5, were not used because of the occurrence of
high instability. When a liposome membrane was destabilized
by Triton X-100, the CF core content is released, and the
fluorescent signal markedly increases (Figure 2A).
CF-loaded liposomes where compared with liposomes of the
same membrane composition but carrying up to 150 mM
sulforhodamine B (SR-B) inside their aqueous core. Lip-
osomes loaded with 150 mM SR-B have been previously
reported as suitable probes for sandwich hybridization assays
for nucleic acid markers.20 Figure 2 shows that a 3-fold
increase in fluorescence intensity was observed when CF
liposomes were treated with Triton X-100. The concentration
of the liposomal nanoparticles was determined by using the
following equation
r
liposomes (nM)
CF 3.97 10
CF ( 5)
tot
8
hydr
3[ ] =
[ ] × ×
[ ] × −
Further information about this equation is reported in the
Supporting Information.
Although sulforhodamine B-loaded liposomes showed a
higher fluorescence increase when treated with Triton X-100,
their minimum detectable liposome concentration was 2
orders of magnitude higher than the detection threshold
determined for CF-loaded liposomes (10−15 for SR-B lip-
osomes vs 10−17 M for CF liposomes, as determined through
subsequent dilutions in Hepes/NaCl buffer; Figure 2B). Even
though SR-B concentration inside liposomes is three times
higher than CF, the improved performance shown by CF-
loaded liposomes might rely on the different quantum yields of
the internalized fluorescent compounds.18,25 These findings
state that CF-loaded nanoparticles are more sensitive at lower
concentrations, giving the possibility to investigate a very low
amount of the target ssDNA and possibly detecting nucleic
acids without the need of an amplification procedure. For these
reasons, CF was used in the further experiments to set up the
proposed assay.
The occurrence of a stable intercalation of cholesteryl-tagged
ssDNA (PROBE) into the phospholipid bilayer was assessed
using high-resolution nuclear magnetic resonance (NMR).
The specific peaks, characteristic of nucleotide sequences,
appeared only in the 1H-NMR spectrum of liposomes
incubated with the PROBE segment, while any nonspecific
signals were detected in the control ones (Figure S1).
Moreover, the number of dialysis cycles needed to eliminate
the nonencapsulated CF from liposome preparation was
evaluated. It was reported that six dialysis cycles (4 h at 4
°C for each cycle) are necessary (Figure S2). In concentrated
suspension, the stability of liposomes has been assessed by
measuring the fluorescence signal intensity of intact liposomes
and Triton X-100-treated liposomes. When CF is released
from liposomes, a fluorescence enhancement occurs (because
of the “dequencing” of leaked CF). As reported in Figure S3,
liposomes are stable up to 4 months.
Procedure Setup and Assay Detection Limit. The
experimental setup takes less than 2 h (Figure S4). During the
first 30 min, magnetic beads, ANCHOR, and TARGET
fragments were mixed to carry out the first annealing step.
During the following 30 min, incubation in the presence of the
PROBE fragment allowed for the fluorescent labeling of the
TARGET. Figure 3 shows the linear range of correlation
between fluorescence intensity and TARGET concentration
(Pearson correlation coefficient = 0.966), with an LOD of 7 ×
10−11 M.26 The entire curve of fluorescence intensity versus
Figure 2. (A) Fluorescence intensity measured at increasing
concentrations of SR-loaded (λex = 565 nm, λem = 583 nm) and
CF-loaded liposomes (λex = 495 nm, λem = 517 nm) before and after
the Triton X-100 addition. (B) Bar plot comparing fluorescence
intensity at the lowest liposome concentrations. Error bars indicate
standard deviation (N = 4).
Figure 3. CF-loaded liposome fluorescence intensity measured after
the addition of increasing TARGET concentrations to the Strep Mag
and ANCHOR mixture. The blue line indicates the background
fluorescence intensity measured without the TARGET (purple lines
show standard error of the mean relative to the noise signal). The red
line was obtained by linear fitting of the data. Error bars indicate
standard deviation (N = 10).
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[DNA Target] is reported in Figure S5, and the parameters of
the calibration curve are reported in Table S1.
After the washing steps, liposomes bound to Strep Mag
beads through the DNA linkage showed a fluorescence
intensity that is not distinguishable from the fluorescence
signal of buffer (Figure 3, green dots). When treated with 0.5%
Triton X-100, fluorescence intensity of the samples showed an
increment directly correlated with the TARGET concentration
(Figure 3, black diamonds). Few liposomes were able to bind
to Strep Mag beads in a nonspecific manner when the
TARGET fragment is not present, producing a low
interference (Figure 3, blue line).
Next, the possibility to further improve the detection limit
using microcuvettes was explored. The advantage of using
microcuvettes relies on an ∼7 times reduction of the final
volume, thus allowing the increase of the dye concentration,
which can allow the discrimination of lower concentrations of
TARGET (e.g., 2 × 10−11M; Figure 4) not detectable by using
the standard cuvettes (as shown by P values obtained by using
Dunnett’s one-way ANOVA).
The same experiment was repeated using SB-R-loaded
liposomes to assess if the use of this dye makes it possible to
reduce the background fluorescence signal. The results, as
reported in Figure S6, confirmed the lower performance of this
dye. In fact, the LOD was 2 orders of magnitude higher than
that of CF-loaded liposomes (2 × 10−10 M).
Figure 5 shows that SCRAMBLE fragments are not able to
link the liposome and the magnetic components. In fact, the
observed fluorescence signal was not distinguishable from the
background in the absence of the TARGET. Furthermore, by
maintaining the scramble-36 and scramble-100 in a 1:1 ratio
and varying the TARGET molarity, no significant interference
in the binding of TARGET to the ANCHOR fragment was
noted, even when the SCRAMBLE:TARGET ratio was
1000:1. In fact, the linearity of the detection of the assay
calibration curve did not vary.
Assay Behavior in the Presence of Double-Stranded
TARGET. The assay response was also evaluated with double
helix conformation of the TARGET fragment (dsTARGET).
To obtain dsTARGET, the single-stranded TARGET was
incubated with its complementary reverse fragment, heated to
85 °C, and then let to cool at room temperature to favor the
correct annealing of the two fragments. The formation of the
dsDNA has been assessed trough agarose gel electrophoresis
(Figure S7).
To allow the assembly of the ANCHOR and PROBE
components to the transient ssTARGET fragments, the
samples were heated at 82 °C for 5 min, and then, the
temperature was rapidly decreased in liquid nitrogen for 10 s.
To avoid the annealing of the two complementary fragments
and favor the binding of the assay components, the
dsTARGET was incubated together with the ANCHOR and
PROBE fragments in a 1:100 molar ratio. Finally, the liposome
was added as the latest component due to its instability at high
temperatures. No significant differences in signal intensity
among the samples incubated at room temperature with
ssTARGET and the ones incubated with dsTARGET were
observed nor among the samples heated to 82 °C (Figure 6).
Adding the Strep Mag beads after the rise in temperature did
not alter the obtained signal intensity, thus suggesting that the
overall decrease might be related to different causes and not
the degradation of the magnetic beads (data not shown).
Assay Behavior in Serum. The effect of different
biological matrices, among which is human serum, was tested
with the aim of investigating the efficiency of the proposed
DNA assay. The ssTARGET was dissolved in human serum
before performing the already described assay. In serum, the
assembly of the probe appears to be greatly hampered (Figure
7 and Figure S8), and the assay detection limit was 2 orders of
magnitude higher, setting the LOD to 0.8 × 10−9 M. These
findings led us to investigate the possibility of unwanted
interactions among serum and assay components, in particular,
Figure 4. Microcuvettes assay. Error bars indicate standard deviation
(N = 4).
Figure 5. (A) Fluorescence intensity of the solution containing
increasing amount of TARGET and a fixed 2 × 10−8 M scramble mix,
added to the Strep Mag ANCHOR mixture. (B) TARGET
concentration is normalized, and signal intensity of the solution
obtained after incubation of TARGET alone is set to 100%. Signal
intensities in the presence of scramble mix are proportionally
calculated and compared to the corresponding TARGET fluorescence
signal. Error bars indicate standard deviation (N = 3).
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with albumin, which is the most abundant serum protein.
However, fluorescence measurements demonstrated that the
presence of albumin did not affect the assembly of the
components and the fluorescence signal intensity (Figure 7).
Further investigations were carried out to determine the role
of phosphates on the decrease of assay performance (i.e.,
increased LOD) in serum. Thus, the assay components were
assembled in PBS buffer prepared with 1 and 10 mM
phosphate concentrations. As seen from albumin, no
significant decrease in the detected fluorescence intensity of
the assay was observed, suggesting that phosphates do not play
a role in the assembly of the deoxyribonucleic nor protein
components (Figure S9). Finally, serum was inactivated
through heating for 25 min at 55 °C and the assay performed
as previously stated. No significant differences among not
treated and treated sera have been observed, suggesting that
the complement is not responsible for the decrease of the assay
performance in this complex biological matrix (Figure S10).
This can be due to the activity of DNase I, one of the
components of the circulating free DNA (cfDNA) elimination
system.27
■ CONCLUSIONS
The herein described assay allows the detection of both single-
and double-stranded DNA, measuring the signal arising from a
fluorescent dye (carboxyfluorescein) encapsulated into lip-
osomes at high concentration and released upon treatment
with detergents (i.e., Triton X-100). The optimized liposomes
are stable for a long period of time (∼4 months) when stored
at high concentration at 4 °C. The LOD of target DNA is 7 ×
10−11 M, making it possible to investigate specific nucleotidic
sequences at very low concentrations. Moreover, in compar-
ison to multistep coupling procedures, the incorporation of a
cholesteryl-modified ssDNA probe was allowed to obtain
targeted liposomes without using expensive coupling reagents
and time-consuming coupling procedures.21,28 Most of the
commonly used techniques (among which are ddPCR and
BEAMing) and sensors for DNA/RNA detection in liquid
biopsies29 have received an in-depth validation for clinical and
preclinical applications.30,31 Compared to the these techniques,
the herein proposed method shows the following advantages:
(i) fast assay (execution time, approximately 2 h); (ii)
simplicity of execution, while both ddPCR and BEAMing
need a medium−high level of expertise to be performed and
require the presence of loader and reader machineries, which
have an elevated price, whose purchase may not be justified for
laboratories not fully dedicated to routinely screen for DNA
markers; (iii) the decrease of biases derived from multiple
amplifications of the low amount of starting nucleotidic
material. Moreover, it is worth to mention the improvements
with respect to the method reported by Baumner et al.,22
namely, (i) a lower LOD (2 orders of magnitude); (ii) the use
of a more efficient fluorescent dye (carboxyfluorescein); (iii)
the use of Triton X-100 to obtain a fluorescence dequencing;
and (iv) the use of magnetic beads instead of immobilized
surfaces that have been proven to be very efficient for this kind
of quantitative assays.32 As previously reported, plasma
concentration values of cell-free DNA in melanoma and lung
cancer patients are ∼36 and 31 ng/mL plasma, respectively.33
The fragment length range is 134−144 bp.25 Thus, using 650
g/mol as the average molecular weight for a base pair, we can
theorize that the plasma cfDNA concentration range for these
patients is 1× 10−10 to 6 × 10−10 M. Considering that the
fraction of mutant DNA ranges from 0.005 to 0.1% of the total
DNA concentration in plasma,34 the expected amount of
mutated DNA in serum is in the 10−13 to 10−15 M range. In the
case of colon carcinoma, the amount of mutant cfDNA
increases dramatically, reaching a value of ∼8%.11,35 This value
is of the order of 10−11 M, that is, in the same order of
magnitude of the LOD of the herein proposed assay, when the
latter is performed in Hepes buffer. In principle, by exploiting a
purification method to extract ctDNA from their biological
matrices, it would be possible to detect and quantify nucleic
acid markers without further amplification. In principle, the
LOD of the herein reported method can be further reduced
(i.e., enhanced assay performance) by using larger liposomes
(e.g, medium unilamellar vesicles or giant liposomes), that is,
containing a higher amount of fluorescent dye encapsulated in
the inner core and/or by using a fluorescent dye with a higher
quantum yield. Furthermore, other items have to be
considered, especially for measurements in serum-containing
specimens. First of all, the role of DNases in degradation of the
target DNA has to be evaluated. For instance, serum DNA
extraction protocols (based on phenol−chloroform extraction
Figure 6. Comparison of assay behavior in the presence of double-
and single-stranded TARGET DNA (means are not significant among
temperature-treated and not treated samples, P value > 0.05). Error
bars indicate standard deviation (N = 3).
Figure 7. Assay behavior in Hepes, Hepes + HSA, and human serum:
fluorescence intensity (a.u.) was measured after the addition of two
concentrations of DNA TARGET (3.3 × 10−10 and 2.0 × 10−9 M) in
three different media (P value > 0.05). Error bars indicate standard
deviation (N = 3).
ACS Omega Article
DOI: 10.1021/acsomega.9b01457
ACS Omega XXXX, XXX, XXX−XXX
E
or pull-down techniques) can be employed to check whether
this may contribute to the loss of sensitivity.
The herein reported method appears suitable, upon proper
optimization, for the screening of circulating cancer DNA. The
developed assay is versatile. In fact, by maintaining the
proposed scheme (liposomes formulation, magnetic beads,
etc.), it is possible to properly design the DNA sequences of
ANCHOR and PROBE to specifically recognize TARGET
sequences. Moreover, considering previously reported works, it
appears possible to expand the herein reported method to the
detection of longer (>36 bp) target DNA molecules.36,37
This is, in principle, applicable to the detection of DNA
circulating in biological fluids (not only circulating tumor
DNA). As an example, one may think of a number of
pathogenic microorganisms that release their DNA in the
bloodstream, thus opening the possibility to exploit their
nucleic acids as markers for characterizing infectious diseases.
Setting the nucleotidic sequence of the ANCHOR and PROBE
fragments on a specific target sequence, the possibilities in the
different markers detectable are limited only by the assay LOD.
Finally, future investigations could also lead to tune and
validate the assay for the detection of RNAs, another class of
diagnostic and prognostic markers rising in interest nowa-
days.38 This class of molecules is more difficult than DNAs to
be analyzed since RNAs are more prone to enzymatic
degradation and because of the complexity and biases present
in RNA amplification protocols.
■ EXPERIMENTAL SESSION
Materials. DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphati-
dylcoline) was purchased from Avanti Polar Lipids (Alabaster,
Alabama, USA). Cholesterol, sodium chloride, sodium
monobasic phosphate, sodium dibasic phosphate, potassium
chloride, Hepes, chloroform, and all other chemicals were
purchased from Sigma-Aldrich Inc. (Merck KGaA, Darmstadt,
Germany). DNA oligonucleotides were purchased from
Eurofin Genomics. Lyophilized human serum (Seronorm)
was purchased from SERO AS, Norway.
Liposome Preparation. Large unilamellar vesicles (LUV)
liposomes were prepared according to the classical thin lipid
film hydration method as previously reported.39−41 Briefly, 45
mg of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphatidylcoline)
were dissolved in a chloroform solution in a 250 mL glass
balloon. The chloroform has been subsequently evaporated by
using a rotavapor device in vacuum conditions at 60 rpm at
room temperature (RT). The lipid film formed after the
solvent evaporation was left stirring for 1.5 h at RT to remove
the presence of any water contamination. Subsequently, 1.5
mL of 50 mM carboxyfluorescein solution, in Hepes buffer
(0.15 M NaCl, 3.8 mM Hepes, pH 7.4, ∼320 mOsm/L), was
added to the lipid film. Then, it was heated through immersion
in a water bath at a temperature of 56 °C, which corresponds
to the transition phase temperature of DPPC phospholipids.
The bottom of the balloon was vortexed at max speed to
ensure the detachment of the film from the glass wall of the
recipient. These heating and vibrating steps were performed
multiple times until the complete lipid film detachment. The
formed solution was then introduced in an extruder device,
heated at 56 °C, and under argon pressure, the vesicles were
forced to pass through a 400 nm filter membrane. After eight
runs, the filter membrane was changed with a 200 nm one, and
other eight runs were performed. To eliminate the unloaded
CF molecules, the LUVs’ suspension (1.5 mL) underwent
extensive dialysis cycles against isotonic Hepes/NaCl buffer
solution (2 L) at 4 °C by using a 14 kDa dialysis cellulose
membrane. The external Hepes solution was replaced every 4 h
for six cycles. After purification, the liposome size was
determined by using dynamic light scattering (DLS)
technology with a Zetasizer Malvern instrument. Liposomes
were then stored at 4 °C in the absence of light to avoid
photobleaching of the fluorescent molecules.42 Under these
storage conditions, liposomes remained stable for at least 4
months.
Cholesteryl−DNA-Tagged Liposome Preparation.
DPPC liposomes (1 × 10−8 M) containing 50 mM CF were
diluted 1:10 in sterile Hepes buffer (150 μL of liposome
solution in 1.35 mL of Hepes buffer). PROBE DNA was then
added to this solution in a 300:1 PROBE/liposome ratio, and
the resultant solution was incubated for 1.5 h on a shaking
ThermoMixer at 4 °C in slow speed in the absence of light.
Subsequently, the solution was dialyzed overnight against 2
L of Hepes buffer in a 16 kDa MWCO dialysis membrane at 4
°C in dark conditions to ensure the elimination of unbound
PROBE molecules. After the dialysis, the functionalized
liposomes were stored at 4 °C in dark conditions.
NMR Characterization. Liposome specimens (20 μL)
have been dissolved in CHCl3 into a 125 mL glass balloon.
This procedure allows destroying liposomes and dissolving all
the apolar molecules. Then, CHCl3 was evaporated using a
rotavapor, and the specimen dissolved into deuterated
methanol.
1H NMR spectra of specimens have been acquired at 4 °C
using a Bruker 600 MHz spectrometer (AVANCE 600, 14
T).43
ssDNA Molecule Design. ssDNA molecules were
purchased from Eurofin Genomics. A quality certificate
describing yield and purification steps of the ordered
oligonucleotide was delivered by the company together with
the product. ssDNAs were artificially designed to be
representatives of DNA sequences occurring in biological
fluids. They have been designed through MeltCalculator, a
Biophysics Integrated DNA Technologies online tool, through
which the presence of self-dimers, hairpins structures, and
annealing temperatures have been calculated.
ssDNAs used in our experiments have the following
sequences:
TARGET: 5′ CTG GAC TGT TGA TTG TGG GAT
TGA TAG GGC GAC TGC 3′.
ANCHOR: 5′-biotin-TEG-GCA GTC GCC CTA TCA
ATC-3′.
PROBE: 5′-CCA CAA TCA ACA GTC CAG-
cholesterol-3′.
RT (reverse target): 5’-GCA GTC GCC CTA TCA
ATC CCA CAA TCA ACA GTC CAG-3’.
S36 (scramble-36): 5′-AGC CGA TCT TAA TGG
ATG GCC GCA GGT GGT ATG GAA-3’.
S100 (scramble-100): 5′-CAA CGG CAT GCG CAA
CTT GTG AAG TGC CTA CTA TCC TTA AAC
GCA TAT CTC GCA CAG TAA CTC CCC AAT
ATG TGA GCA TCT GAT GTT GCC CGG GCC
GAG T-3′.
Lyophilized ssDNAs were rehydrated with sterile Tris-
EDTA solution to obtain a final concentration of 100 μM.
Purity of the shipped ssDNA samples was guaranteed by the
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manufacturer company and subsequently double-checked in
our lab trough Nanodrop analysis.
Double-stranded TARGET DNA has been obtained through
mixing the two complementary fragments TARGET and
REVERSE TARGET in equimolar amounts, heating to 82 °C,
and letting it cure at room temperature to assure the correct
annealing of these two ssDNAs.
Assay Protocol. Sterile Hepes buffer (3 mL) was added to
a 15 mL Falcon tube, and 3 μL of streptavidin-coated magnetic
beads were added (Streptavidin Mag Sepharose, GE Health-
care S.P.A.). A 3 μL ANCHOR ssDNA 100 μM solution was
added to this solution together with the desired amount of
TARGET ssDNA. The Falcon tubes were placed on a shaker,
and the beads and DNA mix were incubated for 30 min at
room temperature to permit the binding of all the probe
components. The tubes were then centrifuged for 2 min at
3000 rpm, and the magnetic beads were retained through a
magnet. The solution was then eliminated together with all the
unbound probe components, and three washing steps were
performed using Hepes buffer. Cholesteryl−PROBE-tagged
liposome (100 μL) was added to the 3 mL Hepes buffer
solution containing the beads and the components bound from
the previous step. This solution was placed for 30 min on a
shaker at medium speed and 4 °C in dark conditions. After this
incubation, the tubes were again centrifuged for 2 min at 3000
rpm. Washing steps were performed to ensure that the
elimination of all the elements was not bound to the magnetic
beads until basal fluorescence intensity was comparable with
the one present in Hepes buffer.
Triton X-100 (0.5%; Sigma-Aldrich) was added to the
liposome solution. After 15 min, the total fluorescence
intensity was analyzed with a spectrofluorometer (Fluoro-
Max-4, Horiba Jobin Yvon). Spectrofluorometric excitation
and emission parameters were set, respectively, at wavelengths
of 492 and 517 nm, wavelengths for carboxyfluorescein
molecules, and at 565 and 586 nm for sulforhodamine B.
In the experiments performed in serum, Strep Mag beads,
ANCHOR, and TARGET ssDNA were directly added to the
serum (human serum, Seronorm SERO AS) and positioned on
a shaker in slow speed at RT for 1 h. Then, the samples were
treated as described above with a centrifugation step, three
washing steps in Hepes buffer, and the addition of DNA−
cholesterol-tagged liposomes.
Data Analysis and Statistic. Data have been obtained by
using at least three independent experiments. The exact
number of replicates has been inserted in each graph.
Data have been reported as mean ± SD.
Pearson correlation coefficient of data in Figure 3 has been
evaluated.
Unpaired two-tailed Student t test has been carried out in
Figures 5 and 6.
Dunnett’s (one-way ANOVA) statistical test has been
applied for the data in Figures 2B and 4. One-way ANOVA
test with Bonferroni correction has been applied for the data in
Figure 7.44
The following legend has been added to the figures: *P value
< 0.05; **P value < 0.01; and ***P value < 0.001.
LOD has been calculated by using the following equation:
LOD = 3σ/m, where σ is the SD of blank and m is the slope of
linear fitting of data in the linear range.
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